This inventor holds 1 USPTO granted patent. Top assignee: Dong-A St Co., Ltd.. Active years: 2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2025
Title: Hyangsoo Lee: Innovator in Pharmaceutical Compounds
Introduction
Hyangsoo Lee is a prominent inventor based in Seoul, South Korea. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that serve as GCN2 inhibitors. His work is crucial for advancing treatments for diseases related to GCN2 activity.
Latest Patents
Hyangsoo Lee holds a patent for "Compounds as GCN inhibitors, pharmaceutical compositions and uses thereof." This patent includes novel compounds, specifically those of Formula (I), which are designed to inhibit the activity of GCN2. The pharmaceutical compositions derived from these compounds can be utilized for treating or preventing diseases associated with GCN2.
Career Highlights
Hyangsoo Lee is affiliated with Dong-a ST Co., Ltd., where he continues to innovate in the pharmaceutical sector. His expertise in developing GCN2 inhibitors positions him as a key player in the industry.
Collaborations
Hyangsoo Lee collaborates with notable colleagues, including Cheonhyoung Park and Kimoon Ryu, to further enhance the research and development of pharmaceutical solutions.
Conclusion
Hyangsoo Lee's contributions to the field of pharmaceuticals, particularly through his patent on GCN2 inhibitors, highlight his role as an influential inventor. His work continues to pave the way for advancements in medical treatments.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile